Pular para o conteúdo principal
Ranking Invest

BCYC - Bicycle Therapeutics plc

Segmento: HealthcareBicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Análise Ranking Invest

Valor de Mercado
$ 267.37 Mi
IVR
-0.45Índice proprietário de comparação relativa: -0,45.
IVR2
-2.55Leitura proprietária complementar: -255%.
MLL
-2.55Leitura proprietária complementar: -255%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 510.25 Mi

Dívida Líquida

-$ 510.05 Mi

L4T

-$ 190.41 Mi

MM4T

-3851.29%

Indicadores Básicos

ROE

-37.32%

Índices de Previsibilidade

Receita Líquida

F0.66

Lucro

B0.20

Margem

E1.46

Índices de Tendência

Receita Líquida

D-1.46

Lucro

F-5.60

Margem

F-6.89

Índices de Endividamento

DIV/PAT

-1.00

DIV/L4T

2.68

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.